Trial Profile
Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms COMPASS
- 20 Nov 2023 Status changed from recruiting to completed.
- 09 Nov 2023 This study has been discontinued in Germany, according to European Clinical Trials Database record.
- 05 Apr 2022 Planned End Date changed from 1 Feb 2022 to 1 Mar 2024.